ArticleEuropean psychiatry : the journal of the Association of European Psychiatrists2021
EPA guidance on treatment of negative symptoms in schizophrenia.
Article in European psychiatry : the journal of the Association of European Psychiatrists, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05911529 (Motivational Interviewing for Patients With Acute Psychosis), which is not on this map. Cited by 116 papers, 8 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Motivational Interviewing for Patients With Acute Psychosis
Who cites it
116 citing papers in PubMed, 8 syntheses or guidelines pooled it.
- Mapping symptom-general and symptom-specific targets for transcranial magnetic stimulation in schizophrenia: an electric-field modeling meta-analysis.Molecular psychiatry · 2026Pooled it
- Peripheral blood immune markers associated with negative symptoms in first episode psychosis: a systematic review.Frontiers in psychiatry · 2026Pooled it
- Memantine for the Treatment of Primary Negative Symptoms in Schizophrenia: A Meta-analysis of Randomized Controlled Trials.Clinical drug investigation · 2025Pooled it
- Pooled it
- Treatments for Social Interaction Impairment in Animal Models of Schizophrenia: A Critical Review and Meta-analysis.Schizophrenia bulletin · 2022Pooled it
- Neural substrates of reward anticipation and outcome in schizophrenia: a meta-analysis of fMRI findings in the monetary incentive delay task.Translational psychiatry · 2022Pooled it
- European Psychiatric Association guidance on assessment of cognitive impairment in schizophrenia.European psychiatry : the journal of the Association of European Psychiatrists · 2022Pooled it
- Systematic Review and Meta-Analysis of Mass Spectrometry Proteomics Applied to Human Peripheral Fluids to Assess Potential Biomarkers of Schizophrenia.International journal of molecular sciences · 2022Pooled it
- A Digital Therapeutic Intervention for Negative Symptoms of Schizophrenia: A Randomized Clinical Trial.JAMA network open · 2026Trial
- Mapping Cerebellar Connectivity to Cognition in Psychosis: Convergent Evidence From Functional Magnetic Resonance Imaging and Transcranial Magnetic Stimulation.Biological psychiatry · 2026Trial
- Mindfulness improves negative psychotic symptoms through reducing emotional and social withdrawal.World journal of psychiatry · 2025Trial
- Decline in Working Memory in Stable Schizophrenia May Be Related to Attentional Impairment: Mediating Effects of Negative Symptoms, a Cross-Sectional Study.Neuropsychiatric disease and treatment · 2024Trial
- Efficacy of low-dose risperidone in combination with sertraline in first-episode drug-naïve patients with schizophrenia: a randomized controlled open-label study.Journal of translational medicine · 2023Trial
- Improvement of adjunctive berberine treatment on negative symptoms in patients with schizophrenia.European archives of psychiatry and clinical neuroscience · 2022Trial
- Expression and experience domains of negative symptoms in relation to social functioning in patients with schizophrenia: Results from a commonality analysis.Schizophrenia research. Cognition · 2026Article
- Low-dose paliperidone combined with sertraline for first-episode and medication-naïve patients with schizophrenia: an open-label, randomized trial.European archives of psychiatry and clinical neuroscience · 2026Article
- Animal Models for Drug Discovery in Schizophrenia: A Critical View from a Clinical Perspective.Pharmaceutical medicine · 2026Review
- Disentangling Anhedonia and Self-Stigma in Schizophrenia Using Bayesian Network Analysis.Alpha psychiatry · 2026Article
- Mentalizing under stress and psychotic experiences: An experience sampling study.Psychology and psychotherapy · 2026Article
- Discrepancies between ideal and actual affect predict negative symptoms in schizophrenia in daily life: An ecological momentary assessment study.Psychiatry research · 2026Article
56 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Negative symptoms of schizophrenia remain a major therapeutic challenge. The progress in the conceptualization and assessment is not yet fully reflected by treatment research. Nevertheless, there is a growing evidence base regarding the effects of biological and psychosocial interventions on negative symptoms. The importance of the distinction between primary and secondary negative symptoms for treatment selection might seem evident, but the currently available evidence remains limited. Good clinical practice is recommended for the treatment of secondary negative symptoms. Antipsychotic treatment should be optimized to avoid secondary negative symptoms due to side effects and due to positive symptoms. For most available interventions, further evidence is needed to formulate sound recommendations for primary, persistent, or predominant negative symptoms.However, based on currently available evidence recommendations for the treatment of undifferentiated negative symptoms (including both primary and secondary negative symptoms) are provided. Although it has proven difficult to formulate an evidence-based recommendation for the choice of an antipsychotic, a switch to a second-generation antipsychotic should be considered for patients who are treated with a first-generation antipsychotic. Antidepressant add-on to antipsychotic treatment is an option. Social skills training is recommended as well as cognitive remediation for patients who also show cognitive impairment. Exercise interventions also have shown promise. Finally, access to treatment and to psychosocial rehabilitation should be ensured for patients with negative symptoms. Overall, there is definitive progress in the field, but further research is clearly needed to develop specific treatments for negative symptoms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.